Section Arrow
Quote
KLRS.NASDAQ
- Kalaris Therapeutics Inc
Quotes are at least 15-min delayed:2025/03/20 18:04 EDT
Last
 11.4
-0.07 (-0.61%)
Day High 
12.9 
Prev. Close
11.47 
1-M High
12.78 
Volume 
74.04K 
Bid
5
Ask
18.18
Day Low
10.3225 
Open
10.3225 
1-M Low
9 
Market Cap 
49.48M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.77 
20-SMA 9.79 
50-SMA 9.8 
52-W High 24.15 
52-W Low 7.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-11.73/--
Enterprise Value
49.48M
Balance Sheet
Book Value Per Share
22.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PSTVPlus Therapeutics1.36+0.849+166.14%-- 
WINTWindtree Therapeutics Inc.2.18+0.49+28.99%0.84PE
IBOImpact BioMedical Inc.2.08+1.55+292.45%-- 
BDTXBlack Diamond Therapeutics1.88+0.16+9.30%-- 
ELEVElevation Oncology0.278-0.1998-41.82%-- 
Quotes are at least 15-min delayed：2025/03/20 18:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.